| Original language | English (US) |
|---|---|
| Pages (from-to) | 3243-3247 |
| Number of pages | 5 |
| Journal | Stroke |
| Volume | 53 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2022 |
Funding
Dr Kim reports grant support from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)‚ NIH/National Institute on Minority Health and Health Disparities (NIMHD)‚ Patient-Centered Outcomes Research Institute (PCORI)‚ and American Heart Association/American Stroke Association (AHA/ASA) and is Associate Editor for NEJM Journal Watch: Neurology. Dr Kamel serves as a principal investigator for the NIH-funded ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke; NINDS U01NS095869), which receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; as Deputy Editor for JAMA Neurology; on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; and on end point adjudication committees for NovoNordisk and Boehringer-Ingelheim. Dr Bernstein reports consulting and speakers relationships with Boehringer-Ingelheim, Pfizer, Amgen, AbbVie, Abbott, Bristol Myers, AstraZeneca, and Medtronic. The other authors report no conflicts.
Keywords
- anticoagulation
- atrial fibrillation
- electrocardiography, ambulatory
- embolic stroke
- ischemic stroke
- risk factors
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
- Advanced and Specialized Nursing
